In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Human Genome Sciences Inc.

Division of GlaxoSmithKline PLC

Latest From Human Genome Sciences Inc.

Inside The Lupus Pipeline: Reasons For Optimism

Several drugs for systemic lupus erythematosus (SLE) and lupus nephritis are in mid-to-late stage development, which could pave the way for new treatments for a disease with few options. Experts say they are energized by the amount of investment in lupus R&D.

Clinical Trials Immune Disorders

Lupus Market Snapshot: There's No Debate It's A Blockbuster Opportunity

Several drug makers are working to bring the next treatment for lupus to market, and the level of interest across the industry suggests the therapeutic area represents a big commercial opportunity.

Market Intelligence Immune Disorders

Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus

Sales of the BLyS inhibitor disappointed at launch, but the franchise is growing double-digits and now a new, more convenient subcutaneous formula will provide another growth opportunity.

Immune Disorders Commercial

GSK's Immunology Strategy Edges Closer To Delivering

GlaxoSmithKline is working to establish an immuno-inflammation portfolio and extend learnings to other therapy areas. Sirukumab could be GSK's first new product in I&I beyond Benlysta. Chief Immunology Officer Paul-Peter Tak outlined his strategy in an interview with Scrip.

Immune Disorders Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • H. Thomas Watkins, Pres. & CEO
    David C Stump, MD, EVP, R&D
    Barry A Labinger, EVP & Chief Commercial Officer
  • Contact Info
  • Human Genome Sciences Inc.
    Phone: (301) 309-8504
    14200 Shady Grove Rd.
    Rockville, MD 20850-7464